Depression treatment is defined by trial and error. We're building the technology to change that.

Eiro is developing prediction tools to match people with the treatments most likely to work for them — cutting through months or years of ineffective care.

Born from
Vanderbilt University Vanderbilt University Medical Center Wellcome Leap MCPsych Program

The problem is structural

Most depression treatment follows a stepwise protocol. Start with one medication. Wait weeks. If it doesn't work, try another. Then another. Layer in therapy. Consider interventional options.

Each step costs time, money, and — most importantly — compounds suffering for someone already in crisis.

This isn't a failure of care. It's a failure of information. We don't have the data to predict what will work for a given individual.

1 in 3
Approximate response rate to a first prescribed antidepressant. For the other two-thirds of people, the process of finding what works is just beginning.

Data-driven treatment selection

Eiro is building software to predict which depression treatments are most likely to be effective for individual patients. Our technology integrates real-world clinical data, treatment histories, and patient-reported outcomes to inform better decisions from day one.

We're pursuing FDA clearance as a Software as a Medical Device (SaMD), because this technology needs to be held to the highest standard of safety and efficacy. This is clinical decision support, not a wellness app.

Building this together

The predictions we're building require something that doesn't exist yet: a large-scale dataset of real depression treatment journeys. What people tried, what happened, and how they're doing now. Eiro Engage is how we're working directly with people to build it.

Learn more →